连花清瘟颗粒联合磷酸奥司他韦胶囊用于流行性感冒的疗效及耐受性分析

Efficacy and tolerance of Lianhua Qingwen capsule combined with oseltamivir phosphate capsule on influenza

目的:探究连花清瘟颗粒联合磷酸奥司他韦胶囊用于流行性感冒的疗效及耐受性。方法:选取2020年1月至2022年1月在我院确诊为流行性感冒的86例患者作为研究对象,使用随机分组方法将所有患者分为观察者和对照组,各43例。对照组患者口服磷酸奥司他韦胶囊进行治疗,观察组患者在对照组的基础上增加冲服连花清瘟颗粒。比较两组患者用药后疗效、症状消失时间以及住院时间、不良反应以及用药前后相关免疫指标以及细胞因子水平。结果:用药后,观察组总有效率明显高于对照组(P<0.05),观察组症状消失时间以及住院时间均明显短于对照组(P<0.05)。用药后,两组CD3+、CD^(4+)水平、CD^(4+)/CD^(8+)比值均比用药前升高,且观察组CD3+、CD^(4+)水平、CD^(4+)/CD^(8+)比值高于对照组(P<0.05);两组白细胞介素-2(Interleukin2,IL-2)、白细胞介素-6(Interleukin-6,IL-6)、肿瘤坏死因子-α(Tumor necrosis factor-α,TNF-α)水平均比用药前下降,且观察组IL-2、IL-6、TNF-α水平明显低于对照组(P<0.05);观察组与对照组的不良反应总发生率无明显差异(P>0.05)。结论:连花清瘟颗粒联合磷酸奥司他韦胶囊用于治疗流行性感冒患者疗效高,可缩短临床症状消失时间以及住院时间,改善T淋巴细胞免疫,降低炎症因子水平,同时安全性高。

Objective:To explore the efficacy and tolerance of Lianhua Qingwen capsule combined with oseltamivir phosphate capsule in the treatment of influenza.Methods:Totally 86 patients who were diagnosed with influenza in the hospital from January 2020 to January 2022 were selected as the research subjects.Using the random grouping method,the enrolled patients were divided into observation group and control group,with 43 cases each.The patients in the control group were treated with oseltamivir phosphate capsule orally while the patients in the observation group were additionally given Lianhua Qingwen granule on the basis of the control group.The efficacy,symptom disappearance time,hospital stay and adverse reactions after medication and levels of relevant immune indicators and cytokines before and after medication were compared between the two groups of patients.Results:After medication,the total effective rate in observation group was significantly higher than that in control group(P<0.05),and the disappearance time of each symptom and hospital stay were significantly shorter than those in control group(P<0.05).The levels of CD3+and CD^(4+)and CD^(4+)/CD^(8+)in the two groups after medication were enhanced compared with those before medication,and the above three indicators were higher in observation group compared to control group(P<0.05).The levels of interleukin-2(IL-2),interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)were reduced in both groups compared with those before medication,and the levels of IL-2,IL-6 and TNF-αwere significantly lower in observation group than those in control group(P<0.05).There was no significant difference in the total incidence rate of adverse reactions between observation group and control group(P>0.05).Conclusion:Lianhua Qingwen capsule combined with oseltamivir phosphate capsule has a high efficacy in the treatment of patients with influenza,and it can shorten the disappearance times of clinical symptoms and hospital stay,improve the T lymphocyte immunity,and reduce the levels of inflammatory factors,and it has high safety.